RYZ101 ((225)Ac-DOTATATE) in patients with estrogen receptor-positive, human epidermal growth factor receptor 2–negative, locally advanced and unresectable, or metastatic breast cancer progressing after prior therapy: The phase 1b/2 TRACY-1 study Meeting Abstract

  

Authors:	Mayer, E. L.; Miller, K.; Jhaveri, K. L.; Yeh, R.; Sakach, E.; Prasad, V.; Ferreira, D. V.; Herszdorfer, P.; Gong, L.; Li, J.; Bodei, L.; Ulaner, G. A.
Abstract Title:	RYZ101 ((225)Ac-DOTATATE) in patients with estrogen receptor-positive, human epidermal growth factor receptor 2–negative, locally advanced and unresectable, or metastatic breast cancer progressing after prior therapy: The phase 1b/2 TRACY-1 study
Meeting Title:	2025 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	43
Issue:	16 Suppl.
Meeting Dates:	2025 May 30-Jun 3
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2025-06-01
DOI:	10.1200/JCO.2025.43.16_suppl.TPS3184
PROVIDER:	EBSCOhost
PROVIDER:	cinahl
DOI/URL:	https://research.ebsco.com/linkprocessor/plink?id=9a9786f4-523b-3bc4-b26d-148d22d04e79
Notes:	Meeting Abstract: TPS3184 -- Source: Cinahl

https://synapse.mskcc.org/synapse/works/has_related_data_chk/226777